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Abstract
Background: This study was done to assess the efficacy and adverse effects of the different doses of adenosine in the pedi-
atric age group with respect to multiple patient variables. 
 Methods: Over a period of 1 year, 86 occasions of supraventricular tachycardia (SVT) were treated with adenosine in 81 
infants and children aged between 18 days and 12 years (median of 1.3 years, SD=3). Adenosine efficacy was evaluated in 
terms of the patients’ demographics, SVT rate, electrocardiogram characteristics, and route of drug administration.
Results: The dose of 50μg/kg was effective only in 24% of the SVT cases, and the additional doses of 100μg/kg, 150μg/kg, 
and 200μg/kg were effective in another 29% of the cases. The drug efficacy was higher in the infants than that in the older 
children. There were no predictors other than age for the estimation of the efficacy of the drug. 
Conclusion: Our findings showed that the current recommended doses of adenosine are ineffective in the vast majority of 
children and infants with SVT. No patient-related factor other than age seems to affect the efficacy of the drug.
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Introduction
Paroxysmal supraventricular tachycardia (SVT) is the 
most common symptomatic arrhythmia in young patients 
and affects children of all ages.1,2 Its prevalence is estimated 
at more than one in 500 children.3,4 The diagnosis of SVT 
is based on thorough clinical history and electrocardiogram 
(ECG). The characteristic features include abrupt onset and 
termination, fixed cycle length, normal QRS complexes, 
and usually an absence of clearly discernible P waves or 
flutter waves.1 SVTs may be divided into many sub-types 
electrophysiologically; however, there are certain general 
principles of therapy which apply to all patients regardless of 
the type of SVT.1,2 Intravenous adenosine is the first line drug 
for the termination of SVT in infants and children.1,2,5-9 Most 
authors recommend an initial dose of 50 to 100μg/kg,1,2,6-9 
while others solely recommend an initial dose of 100μg/kg;10 
be that as it may, if such doses are ineffective, following 
doses by increments of 50μg/kg are recommended. 
There are considerable controversies in the effectiveness 
and dosing of adenosine.11-13 Patient-dependent factors such 
as heart rate and administration route are thought to be the 
predictive factors for the effectiveness of adenosine in a few 
studies,14,15 while others do not find such results. The side 
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effects of the drug also remain controversial.6,16,17  
The aim of this study was to assess the effectiveness of the 
different doses of adenosine, as well as its side effects while 
considering multiple patient variables.
Methods 
We conducted a prospective observational study on 
hospitalized children between November 2006 and 2007. 
During this period, 86 episodes of SVT in 81 patients (40 male 
and 41 female) were treated with intravenous adenosine. The 
diagnosis of SVT was based on clinical and ECG findings. 
The criteria for the rapid diagnosis of SVT were: 1- abrupt 
onset of arrhythmia, 2- fixed cycle length, 3- normal QRS 
complex duration, 4- uniform QRS complexes, 5- absence of 
clearly discernible P waves or flutter waves, and 6- heart rate 
of more than 180 per minute.  
The patients were managed by pediatric cardiology 
fellows and trained staff in the emergency department, 
pediatric intensive care units, pediatric ward, and cardiac 
catheterization laboratory. All the patients were monitored 
continuously with a single-lead ECG from admission until 24 
hours after the termination of the tachycardia and restoration 
of permanent sinus rhythm. The heart rate was recorded 
just before the administration of each dose of adenosine. 
A 12-lead ECG was obtained from all the patients after the 
termination of the tachycardia and was analyzed for P wave 
characteristics, PR interval, QRS axis and duration, presence 
of a delta wave, and calculation of corrected QT interval.
Adenosine was prepared as a sterile solution in 0.9% 
sodium chloride with 1mg/ml concentration. Each bolus was 
flashed immediately with physiological saline.
The route of drug administration was peripheral venous 
access in 48 episodes (right arm in 24, left arm in 14, right 
leg in 6, and left leg in 4) and central venous access in 38. 
The data were analyzed with the Statistical Package for 
Social Sciences (SPSS, Chicago, IL) software (version 
15.0) using conventional methods for mean and SDs. The 
comparisons between the groups were made by means of the 
non-parametric Mann-Whitney, Fisher, and Chi-square tests. 
P values of less than 0.05 were considered significant.
Results
The patients were between 18 days and 12 years of age 
(median=1.3, SD=3 years). Thirty-nine episodes occurred 
in the infants (aged 1 year or less), and the remainder in the 
older children. The weight of the patients ranged from 3 to 23 
kg (median=8.2kg). Sixty-six patients had structural cardiac 
anomalies, while 38 of them had undergone palliative or 
corrective interventions. The types of congenital heart disease 
(CHD) and relative interventions are summarized in Figure 1. 

Figure 1. Types of structural heart disease and interventions in supraventricular tachycardia patients
DTGA, d- transposition of great arteries; TOF, Tetralogy of Fallot; TAPVC, Total anomalous pulmonary venous connection; AVSD,  Atrioventricular septal 
defect; PDA, Patent ductus arteriosus; VSD, Ventricular septal defect; MVP, Mitral valve prolapse; AS, Aortic stenosis; PS, Pulmonary valve stenosis
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Sixteen patients had a previous history of SVT. Fifteen 
patients used digoxin as a cardiac inotrope. Six patients had 
the Wolff-Parkinson-White (WPW) pattern on their surface 
ECG; two of them had a history of SVT and used propranolol. 
The patients’ characteristics are summarized in Table 1.
Table 1. Patients’ characteristics (n=81)*
Male 40 (49)
Infantile age 39 (48)
Older than 1 year 42 (52)
Structural cardiac anomaly (other than PFO and BAV) 66 (81)
Previous surgical intervention 38 (47)
History of SVT 16 (20)
Digoxin usage 15 (19)
Propranolol  usage 2 (2)
Wolf- Parkinson-White Syndrome 6 (7)
*Numbers in the parentheses show the related percentages
PFO, Patent foramen ovale; BAV, Bicuspid aortic valve; SVT, 
Supraventricular tachycardia  
The patients were divided into 2 age groups according 
to different reported results in previous studies.13,15 Group I 
(infants group) comprised 37 patients (18 males) at the age of 
1 year or less, and Group II (children group) consisted of 44 
patients (22 males). 
In 20 patients vagal maneuvers had been tried before 
adenosine administration without any success. Adenosine was 
given to 81 patients for 86 episodes of SVT.
The initial dose was 50μg/kg in 76 episodes and 100μg/kg 
in 10. The starting dose of 100μg/kg was based on personal 
physician judgment without any protocol or patient difference. 
With each dose, the cycle of arrhythmia was broken initially in 
many episodes but early re-initiation of arrhythmia occurred in 
some. In the most persistent episodes, higher doses of the drug 
were administered after 2-4 minutes. Many persistent episodes 
were treated with other drugs in the course of treatment. 
The effects of the different doses of adenosine and type of 
management in the persistent episodes are summarized in 
Table 2. Because of the short half-life of adenosine (less than 
15 seconds), the accumulation effect was not considered.
In 35 (40.7%) episodes arrhythmia was not stopped 
by the current doses of adenosine; it was ineffective in 8 
(20.5%) infants and 27 (57.4%) children. This difference 
was statistically significant (p<0.001). Permanent control 
of arrhythmia with adenosine by doses up to 200μg/kg was 
69.2% in the infants compared with 40.4% in the older 
children (p=0.008).
Factors other than age (sex, history of previous SVT, 
presence of CHD, previous cardiac surgery, anti-arrhythmic 
drug use, SVT rate, ECG characteristics, and route of 
drug administration) were not correlated statistically with 
adenosine efficacy.
All the patients who did not respond to adenosine were 
treated with other usual anti-arrhythmic drugs successfully 
(18 episodes with amiodarone, 12 with verapamil, 4 with 
digoxin, 4 with propranolol, and 2 with procainamide). No 
patient needed cardioversion.
No important side effect was detected after the 
administration of adenosine; note that transient complete 
heart block was not considered as a drug adverse effect. 
Discussion
Adenosine is a purine nucleoside with a half-life of 15-30 
seconds in humans.11 Its mechanism of action includes a 
direct effect on the activation of the adenosine-sensitive 
potassium current.18 The increase in potassium conductance 
shortens atrial action potential duration, hyperpolarizes the 
membrane potential, and decreases atrial contractility. 
Similar changes occur in the sinus and atrioventricular 
(AV) nodes. In addition to these direct effects, adenosine 
antagonizes catecholamine-stimulated adenylate cyclase 
activity.18 When administered as a rapid intravenous 
bolus, adenosine should produce transient AV node block, 
terminating tachycardia using the AV node.19 These effects on 
the AV node and  sinuatrial (SA) node will be brief, allowing 
normal sinus rhythm to resume. Even if the AV node block 
fails to terminate tachycardia, the resultant alteration in the 
AV relationship provides important diagnostic information.
Table 2. Treatment results in 86 episodes of supraventricular tachycardia in our study*
Adenosine dose Completely controlled 
episodes 
Transiently controlled 
episodes 
Uncontrolled 
episodes
Controlled episodes with other drugs
50μg/kg
(used for 76 episodes)
18 10 48 2
(Verapamil: 2)
100μg/kg
(used for 66 episodes)
8 20 38 8
(Amiodarone: 4
Verapamil: 4)
150μg/kg
(used for 50 episodes)
16 13 21 22
 (Amiodarone: 8
Verapamil: 6
Digoxin: 4
Propranolol: 4)
200μg/kg
(used for 12 episodes)
4 4 4 8
(Amiodarone: 6
    procainamide: 2)
*Adenosine was used 204 times for 86 episodes of supraventricular tachycardia (some episodes needed more than one dose of the drug). In 46 (53%) of the 
episodes, it was effective. All non-responding episodes to adenosine were treated with other antiarrhythmic drugs successfully.
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 Primary atrial tachycardia or ventricular tachycardia 
occasionally may be terminated by adenosine.1 Reinitiating 
of tachycardia may limit the clinical efficacy of this drug.  A 
possible mechanism is the sinus acceleration that follows a 
bolus dose. This is a common mechanism of the initiation of 
SVT in small infants.19 
The initial recommended dose of adenosine varies between 
50 to 150μg/kg. Most authors recommend an initial dose 
of 50 to 100μg/kg,1,2,6-9 while others solely recommend an 
initial dose of 100μg/kg.10 Overholt et al.20 reported a mean 
effective dose of 114-131 μg/kg. Till et al.6 found a median 
dose of 150μg/kg to be effective. Dixon et al.12 reported that 
the dose of 50 μg/kg was effective in less than 10% of infants 
and children and that the dose of 100μg/kg was effective in 
less than 25% of infants and 50% of children. 
Sherwood et al.10 found a 16% response to 50μg/kg. Losek 
et al.9 showed a 22% efficacy for doses up to 100μg/kg.
We found that the dose of 50μg/kg was effective in 24%, 
doses up to 100μg/kg in 30%, doses up to 150μg/kg in 49%, 
and doses up to 200μg/kg in 53% of the cases.  
A few researchers have reported the effect of SVT rate14 and 
route of drug administration15 on the efficacy of the drug. We 
studied multiple factors, including patient demographics (age, 
sex), patient history (previous SVT, CHD, antiarrhythmic 
drug use, and previous cardiac surgery), SVT rate, basal ECG 
characteristics (rate and rhythms, P wave characteristics, PR 
interval, QRS axis and duration, presence of delta wave, and 
QTC), and route of drug administration. We found that none 
of these factors other than age influenced the efficacy of the 
drug.
Dixon et al.6 found a lower response to adenosine in infants 
compared to children. Contrary to their findings, we found a 
higher response to adenosine in the infants by comparison 
with the children (69% vs. 40%, P=0.008). 
Some researchers have demonstrated the side effects of 
the drug.10,14 We found no important side effects after the 
administration of adenosine; it is worthy of note, however, 
that we did not consider transient complete heart block as a 
drug adverse effect. 
Conclusion
Our findings showed that the current recommended 
adenosine doses for the acute management of SVT might be 
ineffective in the vast majority of cases. Chiming in with some 
previous studies, the present study highlights the need for a 
review of the dose protocol of adenosine in SVT. We would 
propose different dose references for infants and children in 
light of significant differences in drug response. Our findings 
confirm that nearly all SVT episodes can be controlled with 
routine drugs and that adenosine is a safe drug with doses up 
to 200 μg/kg.
We found that multiple patient variables such as sex, history 
of previous SVT, presence of CHD, previous cardiac surgery, 
anti-arrhythmic drug use, SVT rate, ECG characteristics, and 
route of drug administration do not affect the efficacy of 
adenosine. 
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